

# Wolfgang Preiser

## List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/2516692/publications.pdf](https://exaly.com/author-pdf/2516692/publications.pdf)

Version: 2025-02-01

140

PR articles

11,426

PR citations

68404

37

PR h-index

20060

104

g-index

173

documents

14112

doc citations

53457

43

h-index

24370

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters. <i>Vaccine</i> , 2024, 42, 738-744.	3.2	4
2	Frequency, kinetics and determinants of viable SARS-CoV-2 in bioaerosols from ambulatory COVID-19 patients infected with the Beta, Delta or Omicron variants. <i>Nature Communications</i> , 2024, 15, .	13.9	12
3	SARS-CoV-2 seroepidemiology in Cape Town, South Africa, and implications for future outbreaks in low-income communities. <i>PLOS Global Public Health</i> , 2024, 4, e0003554.	2.2	1
4	An Oxford Nanopore Technology-Based Hepatitis B Virus Sequencing Protocol Suitable for Genomic Surveillance Within Clinical Diagnostic Settings. <i>International Journal of Molecular Sciences</i> , 2024, 25, 11702.	4.5	1
5	Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection With accumulation of mutations in a patient with poorly controlled Human Immunodeficiency Virus infection. <i>Clinical Infectious Diseases</i> , 2023, 76, e522-e525.	5.4	47
6	A tale of two waves: characteristics and outcomes of COVID-19 admissions during the Omicron-driven fourth wave in Cape Town, South Africa, and implications for the future. <i>IJID Regions</i> , 2023, 6, 42-47.	1.6	4
7	LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters. <i>Viruses</i> , 2023, 15, 1409.	3.3	5
8	How South Africa Used National Cycle Threshold (Ct) Values to Continuously Monitor SARS-CoV-2 Laboratory Test Quality. <i>Diagnostics</i> , 2023, 13, 2554.	3.0	3
9	Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 483-491.	3.2	17
10	Tracking the circulating SARS-CoV-2 variant of concern in South Africa using wastewater-based epidemiology. <i>Scientific Reports</i> , 2022, 12, .	3.5	38
11	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. <i>Nature</i> , 2022, , .	39.5	69
12	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. <i>Nature</i> , 2022, 603, 679-686.	39.5	1,636
13	Reduced amplification efficiency of the RNA-dependent-RNA-polymerase target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests. <i>Journal of Virological Methods</i> , 2022, 302, 114471.	1.7	8
14	Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. <i>Nature Communications</i> , 2022, 13, .	13.9	34
15	Challenges and complexities in evaluating severe acute respiratory syndrome coronavirus 2 molecular diagnostics during the COVID-19 pandemic. <i>African Journal of Laboratory Medicine</i> , 2022, 11, .	0.7	5
16	Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections – a survival analysis. <i>International Journal of Infectious Diseases</i> , 2022, 118, 150-154.	2.2	24
17	Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. <i>Tropical Medicine and International Health</i> , 2022, 27, 564-573.	2.0	119
18	Delays in HIV-1 infant polymerase chain reaction testing may leave children without confirmed diagnoses in the Western Cape province, South Africa. <i>African Journal of Laboratory Medicine</i> , 2022, 11, .	0.7	1

#	ARTICLE	IF	PR CITATIONS
19	Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. <i>Nature Medicine</i> , 2022, 28, 1785-1790.	40.4	617
20	Higher mortality associated with the SARS-CoV-2 Delta variant in the Western Cape, South Africa, using RdRp target delay as a proxy: a cross-sectional study.. <i>Gates Open Research</i> , 2022, 6, 117.	0.7	0
21	The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance. <i>Science</i> , 2022, 378, .	37.0	149
22	From Easing Lockdowns to Scaling Up Community-based Coronavirus Disease 2019 Screening, Testing, and Contact Tracing in Africaâ€”Shared Approaches, Innovations, and Challenges to Minimize Morbidity and Mortality. <i>Clinical Infectious Diseases</i> , 2021, 72, 327-331.	5.4	60
23	HIV false positive screening serology due to sample contamination reduced by a dedicated sample and platform in a high prevalence environment. <i>PLoS ONE</i> , 2021, 16, e0245189.	2.4	3
24	Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa. <i>PLoS ONE</i> , 2021, 16, e0247852.	2.4	51
25	Multiple Early Introductions of SARS-CoV-2 to Cape Town, South Africa. <i>Viruses</i> , 2021, 13, 526.	3.3	22
26	Detection of a SARS-CoV-2 variant of concern in South Africa. <i>Nature</i> , 2021, 592, 438-443.	39.5	1,609
27	Wastewater treatment works change the intestinal microbiomes of insectivorous bats. <i>PLoS ONE</i> , 2021, 16, e0247475.	2.4	13
28	Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis. <i>Vaccine</i> , 2021, 39, 3141-3151.	3.2	12
29	Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review. <i>BMC Cancer</i> , 2021, 21, .	3.1	17
30	Molecular characterisation and epidemiology of enterovirus-associated aseptic meningitis in the Western and Eastern Cape Provinces, South Africa 2018â€”2019. <i>Journal of Clinical Virology</i> , 2021, 139, 104845.	3.1	16
31	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. <i>Cell Host and Microbe</i> , 2021, 29, 1093-1110.	15.5	94
32	Xpert HPV as a Screening Tool for Anal Histologic High-Grade Squamous Intraepithelial Lesions in Women Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 978-984.	1.8	6
33	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. <i>Science</i> , 2021, 374, 423-431.	37.0	198
34	Hepatitis B virus-associated hepatocellular carcinoma in South Africa in the era of HIV. <i>BMC Gastroenterology</i> , 2020, 20, .	2.4	25
35	Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults. <i>Journal of Clinical Virology</i> , 2020, 129, 104548.	3.1	24
36	Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia. <i>PLoS ONE</i> , 2020, 15, e0238839.	2.4	3

#	ARTICLE	IF	PR CITATIONS
37	Turnaround times – the Achilles™ heel of community screening and testing in Cape Town, South Africa: A short report. <i>African Journal of Primary Health Care and Family Medicine</i> , 2020, 12, .	1.0	8
38	Treatment advantage in HBV/HIV coinfection compared to HBV mono-infection in a South African cohort. <i>Journal of Infection</i> , 2020, 81, 121-130.	2.9	28
39	Optimising influenza vaccination during a SARS-CoV-2 epidemic in South Africa could help maintain the integrity of our healthcare system. <i>South African Medical Journal</i> , 2020, 110, 259.	0.7	2
40	Prevalence of chronic HBV infection in pregnant women attending antenatal care in a tertiary hospital in Mwanza, Tanzania: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2020, 20, .	2.8	20
41	Prevalence and risks of hepatitis E virus infection in blood donors from the Western Cape, South Africa. <i>Vox Sanguinis</i> , 2020, 115, 695-702.	1.2	16
42	High positive HIV serology results can still be false positive. <i>IDCases</i> , 2020, 21, e00849.	0.8	13
43	COVID-19: Getting ahead of the epidemic curve by early implementation of social distancing. <i>South African Medical Journal</i> , 2020, 110, 258.	0.7	28
44	Viral hepatitis B and C in HIV-exposed South African infants. <i>BMC Pediatrics</i> , 2020, 20, .	1.9	3
45	Diagnosis of COVID-19: Considerations, Controversies and Challenges in South Africa. <i>Wits Journal of Clinical Medicine</i> , 2020, 2, 3.	0.2	12
46	Pooled testing: A tool to increase efficiency of infant HIV diagnosis and virological monitoring. <i>African Journal of Laboratory Medicine</i> , 2020, 9, .	0.7	5
47	Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, .	1.2	46
48	Responding to the Challenge of the Dual COVID-19 and Ebola Epidemics in the Democratic Republic of Congo – Priorities for Achieving Control. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 597-602.	0.0	52
49	Academic publishing in pandemic times. <i>South African Journal of Science</i> , 2020, 116, .	1.0	1
50	Lessons in diagnostic virology: expected and unexpected sources of error. <i>Reviews in Medical Virology</i> , 2019, 29, .	7.1	28
51	Pooled PCR testing of dried blood spots for infant HIV diagnosis is cost efficient and accurate. <i>BMC Infectious Diseases</i> , 2019, 19, .	2.8	9
52	Congenital Rubella Syndrome Surveillance in South Africa Using a Sentinel Site Approach: A Cross-sectional Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1658-1664.	5.4	15
53	Attempted molecular detection of the thermally dimorphic human fungal pathogen <i>Emergomyces africanus</i> in terrestrial small mammals in South Africa. <i>Medical Mycology</i> , 2018, 56, 510-513.	0.6	18
54	HBV and HIV viral load but not microbial translocation or immune activation are associated with liver fibrosis among patients in South Africa. <i>BMC Infectious Diseases</i> , 2018, 18, .	2.8	24

#	ARTICLE	IF	PR CITATIONS
55	HIV-1 RNA testing of pooled dried blood spots is feasible to diagnose acute HIV infection in resource limited settings. <i>Southern African Journal of Infectious Diseases</i> , 2018, 33, 50-53.	0.4	1
56	HIV-1 RNA testing of pooled dried blood spots is feasible to diagnose acute HIV infection in resource limited settings. <i>Southern African Journal of Infectious Diseases</i> , 2018, 33, 50-53.	0.4	0
57	Racial differences in seroprevalence of HAV and HEV in blood donors in the Western Cape, South Africa: a clue to the predominant HEV genotype?. <i>Epidemiology and Infection</i> , 2017, 145, 1910-1912.	2.0	15
58	Interpretation of indeterminate HIV-1 PCR results are influenced by changing vertical transmission prevention regimens. <i>Journal of Clinical Virology</i> , 2017, 95, 86-89.	3.1	6
59	Moderate levels of preantiretroviral therapy drug resistance in a generalized epidemic. <i>Aids</i> , 2017, 31, 2387-2391.	2.5	7
60	Point-of-care screening for hepatitis B virus infection in pregnant women at an antenatal clinic: A South African experience. <i>PLoS ONE</i> , 2017, 12, e0181267.	2.4	45
61	Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial. <i>PLoS ONE</i> , 2016, 11, e0146678.	2.4	21
62	Mutational Heterogeneity in p6 Gag Late Assembly (L) Domains in HIV-1 Subtype C Viruses from South Africa. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 80-84.	1.5	15
63	Novel Arenavirus Isolates from Namaqua Rock Mice, Namibia, Southern Africa. <i>Emerging Infectious Diseases</i> , 2015, 21, 1213-1216.	3.9	11
64	The HIV/HBV co-infected patient: Time for proactive management. <i>South African Medical Journal</i> , 2015, 105, 281.	0.7	4
65	Hepatitis E virus infection: An underdiagnosed infection in transplant patients in Southern Africa?. <i>Journal of Clinical Virology</i> , 2015, 70, 23-25.	3.1	12
66	Evolutionary origins of hepatitis A virus in small mammals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15190-15195.	7.8	124
67	Hepatitis B virus infection in HIV-exposed infants in the Western Cape, South Africa. <i>Vaccine</i> , 2015, 33, 4618-4622.	3.2	24
68	Altered Innate Immune Development in HIV-Exposed Uninfected Infants. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 245-255.	1.8	77
69	Hantaviruses in Africa. <i>Virus Research</i> , 2014, 187, 34-42.	2.6	51
70	Irreproducible positive results on the Cobas AmpliPrep/Cobas TaqMan HIV-1 Qual test are different qualitatively from confirmed positive results. <i>Journal of Medical Virology</i> , 2014, 86, 82-87.	3.8	19
71	Rooting the Phylogenetic Tree of Middle East Respiratory Syndrome Coronavirus by Characterization of a Conspecific Virus from an African Bat. <i>Journal of Virology</i> , 2014, 88, 11297-11303.	3.7	369
72	A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy. <i>Journal of Clinical Virology</i> , 2014, 60, 387-391.	3.1	9

#	ARTICLE	IF	PR CITATIONS
73	The epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa. <i>Vaccine</i> , 2013, 31, 5579-5584.	3.2	65
74	Pooled HIV-1 Viral Load Testing Using Dried Blood Spots to Reduce the Cost of Monitoring Antiretroviral Treatment in a Resource-Limited Setting. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, 134-137.	1.8	24
75	Close Relative of Human Middle East Respiratory Syndrome Coronavirus in Bat, South Africa. <i>Emerging Infectious Diseases</i> , 2013, 19, 1697-1699.	3.9	347
76	Antibody Responses to Vaccination among South African HIV-Exposed and Unexposed Uninfected Infants during the First 2 Years of Life. <i>Vaccine Journal</i> , 2013, 20, 33-38.	3.0	78
77	Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens. <i>PLoS ONE</i> , 2013, 8, e67188.	2.4	63
78	Construction of a High Titer Infectious HIV-1 Subtype C Proviral Clone from South Africa. <i>Viruses</i> , 2012, 4, 1830-1843.	3.3	2
79	High HBV Viral Loads in HIV-Infected Pregnant Women at a Tertiary Hospital, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, e111-e112.	1.8	19
80	Establishing diagnostic cut-off criteria for the COBAS AmpliPrep/COBAS TaqMan HIV-1 Qualitative test through validation against the Amplicor DNA test v1.5 for infant diagnosis using dried blood spots. <i>Journal of Clinical Virology</i> , 2012, 53, 106-109.	3.1	31
81	Ontogeny of Toll-Like Receptor Mediated Cytokine Responses of South African Infants throughout the First Year of Life. <i>PLoS ONE</i> , 2012, 7, e44763.	2.4	36
82	HIV Drug Resistance (HIVDR) in Antiretroviral Therapy-Naïve Patients in Tanzania Not Eligible for WHO Threshold HIVDR Survey Is Dramatically High. <i>PLoS ONE</i> , 2011, 6, e23091.	2.4	46
83	Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. <i>Journal of Medical Virology</i> , 2011, 83, 1764-1769.	3.8	35
84	Optimising automation of a manual enzyme-linked immunosorbent assay. <i>African Journal of Laboratory Medicine</i> , 2011, 1, .	0.7	1
85	Pooling Strategies to Reduce the Cost of HIV-1 RNA Load Monitoring in a Resource-Limited Setting. <i>Clinical Infectious Diseases</i> , 2011, 52, 264-270.	5.4	56
86	HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts. <i>Infectious Disorders - Drug Targets</i> , 2011, 11, 167-174.	1.1	236
87	Significantly Diminished Long-Term Specificity of the BED Capture Enzyme Immunoassay Among Patients With HIV-1 With Very Low CD4 Counts and Those on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 53, 496-499.	1.8	64
88	NucliSens EasyQ <sup>®</sup> HIV-1 V1.2 system: Detection of human plasma-derived background signal. <i>Journal of Virological Methods</i> , 2010, 165, 318-319.	1.7	5
89	Young age a predictor of weak reactivity in a rapid antibody test in infants infected with HIV. <i>Journal of Medical Virology</i> , 2010, 82, 1314-1317.	3.8	4
90	Klinik, Epidemiologie und Diagnostik tropischer Virusinfektionen. <i>Tropische Viren nicht nur in den Tropen. Pharmazie in Unserer Zeit</i> , 2010, 39, 34-40.	0.0	4

#	ARTICLE	IF	PR CITATIONS
91	Pandemic influenza A (H1N1) 2009: the experience of the first six months. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 11-21.	2.4	15
92	Prevalence- and Gender-Specific Immune Response to Opportunistic Infections in HIV-Infected Patients in Lesotho. <i>Sexually Transmitted Diseases</i> , 2010, 37, 454-459.	1.3	21
93	Extraction buffer contaminated bacterially as a cause of invalid HIV-1 viral load results on the NucliSens EasyQ <sup>®</sup> system. <i>Journal of Virological Methods</i> , 2008, 150, 80-81.	1.7	5
94	Reconstitution of Cytomegalovirus Specific T Cells after Pediatric Allogeneic Stem Cell Transplantation: Results from a Pilot Study Using a Multi-Allele CMV Tetramer Group. <i>Klinische Padiatrie</i> , 2008, 220, 348-352.	0.6	12
95	Cytomegalovirus-specific CD4 T-cell and glycoprotein B specific antibody response in recipients of allogeneic stem cell transplantation. <i>Journal of Clinical Virology</i> , 2006, 35, 160-166.	3.1	8
96	Pitfalls with rapid HIV antibody testing in HIV-infected children in the Western Cape, South Africa. <i>Journal of Clinical Virology</i> , 2006, 37, 68-71.	3.1	31
97	Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants. <i>PLoS Medicine</i> , 2006, 3, e237.	8.1	656
98	Ultrasensitive Monitoring of HIV-1 Viral Load by a Low-Cost Real-Time Reverse Transcription-PCR Assay with Internal Control for the 5' Long Terminal Repeat Domain. <i>Clinical Chemistry</i> , 2006, 52, 1258-1266.	1.1	93
99	Anti-HIV, Anti-Poxvirus, and Anti-SARS Activity of a Nontoxic, Acidic Plant Extract from the <i>Trifolium</i> Species <i>Secometacv</i> /anti-vac Suggests That It Contains a Novel Broad-Spectrum Antiviral. <i>Annals of the New York Academy of Sciences</i> , 2005, 1056, 293-302.	4.5	39
100	Development of antiviral therapy for severe acute respiratory syndrome. <i>Antiviral Research</i> , 2005, 66, 81-97.	3.9	64
101	Kommerzielle Systeme zur Genotypisierung von humanen Immundefizienzviren Typ 1: Vergleich von ViroSeq (Abbott) und TruGene (Bayer). Commercially available assays for genotyping of human immunodeficiency virus type 1: Comparison of ViroSeq (Abbott) and TruGene (Bayer). <i>Das Medizinische Laboratorium</i> , 2005, 29, 50-62.	0.0	0
102	Comparative evaluation of the Cobas Amplicor HIV-1 Monitor <sup>®</sup> , <sup>®</sup> Ultrasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor <sup>®</sup> , <sup>®</sup> Ultrasensitive Test and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples. <i>Journal of Clinical Virology</i> , 2005, 33, 43-51.	3.1	32
103	HBV reactivation after kidney transplantation. <i>Journal of Clinical Virology</i> , 2005, 32, 162-165.	3.1	63
104	Neue Methoden in der Zytomegalievirus-Diagnostik. <i>Deutsche Medizinische Wochenschrift</i> , 2004, 129, 1509-1512.	0.2	1
105	Activation of the Cytokine Network and Unfavorable Outcome in Patients with Yellow Fever. <i>Journal of Infectious Diseases</i> , 2004, 190, 1821-1827.	3.9	100
106	Das SARS-assoziierte Coronavirus "Die erste Pandemie des 21. Jahrhunderts / The SARS-associated coronavirus" The first pandemic of the 21st century. <i>Laboratoriums Medizin</i> , 2004, 28, 42-55.	0.2	0
107	Evaluation of Advanced Reverse Transcription-PCR Assays and an Alternative PCR Target Region for Detection of Severe Acute Respiratory Syndrome-Associated Coronavirus. <i>Journal of Clinical Microbiology</i> , 2004, 42, 2043-2047.	4.1	100
108	NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissions. <i>Transfusion</i> , 2004, 44, 470-475.	0.8	25

#	ARTICLE	IF	PR CITATIONS
109	Severe acute respiratory syndrome (SARS)â€™ paradigm of an emerging viral infection. Journal of Clinical Virology, 2004, 29, 13-22.	3.1	111
110	Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet, The, 2004, 363, 2139-2141.	52.0	259
111	Stability and inactivation of SARS coronavirus. Medical Microbiology and Immunology, 2004, 194, 1-6.	3.0	499
112	Primary Cytomegalovirus Infection in an Outpatient Settingâ€™ Laboratory Markers and Clinical Aspects. Infection, 2003, 31, 318-323.	3.2	48
113	Development and clinical application of a fully controlled quantitative PCR assay for cell-free cytomegalovirus in human plasma. Journal of Clinical Virology, 2003, 26, 49-59.	3.1	24
114	Severe acute respiratory syndrome: identification of the etiological agent. Trends in Molecular Medicine, 2003, 9, 325-327.	7.7	100
115	Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. New England Journal of Medicine, 2003, 348, 1967-1976.	44.0	4,208
116	Klinik und Behandlung des schweren akuten respiratorischen Syndroms. Deutsche Medizinische Wochenschrift, 2003, 128, 1109-1114.	0.2	11
117	Role of China in the Quest To Define and Control Severe Acute Respiratory Syndrome. Emerging Infectious Diseases, 2003, 9, 1037-1041.	3.9	54
118	Variety of Interpretation Systems for Human Immunodeficiency Virus Type 1 Genotyping: Confirmatory Information or Additional Confusion?. Current Drug Targets Infectious Disorders, 2003, 3, 373-382.	2.1	26
119	Chemotherapeutika-Resistenz und neue Virusvarianten bei sexuell Ã¼bertragbaren Infektionen/Chemotherapeutic Resistance and Novel Virus Variants in Sexually Transmitted Infections. Laboratoriums Medizin, 2002, 26, 474-485.	0.2	0
120	Quantifizierung von CMV-DNA als diagnostisches Werkzeug zur verbesserten Behandlung und berwachung von Risikopatienten/CMV Genome Quantification as a Diagnostic Tool for Improving Treatment and Monitoring of Risk Patients. Laboratoriums Medizin, 2002, 26, 486-494.	0.2	0
121	HHV-8 SeroprÃ¤valenz in ausgewÃ¤hlten (Risiko)-Kollektiven im Raum Frankfurt am Main/HHV-8 Seroprevalence in Selected (Risk)-Groups in the Area of Frankfurt am Main. Laboratoriums Medizin, 2002, 26, 466-473.	0.2	0
122	Viral genome quantification as a tool for improving patient management: the example of HIV, HBV, HCV and CMV. Journal of Antimicrobial Chemotherapy, 2002, 49, 713-721.	3.2	33
123	Evaluation of the Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitorâ€™,â„¢ Ultrasensitive Test: comparison with the Cobas Amplicor HIV-1 Monitorâ€™,â„¢ test (manual specimen preparation). Journal of Clinical Virology, 2002, 25, 103-107.	3.1	25
124	Performance characteristics of an automated PCR assay for the quantification of cytomegalovirus DNA in plasma. Journal of Virological Methods, 2002, 101, 149-157.	1.7	15
125	Virology and epidemiology of oral herpesvirus infections. Medical Microbiology and Immunology, 2002, 192, 133-136.	3.0	2
126	The role of viral load determination for the management of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection. Journal of Clinical Virology, 2001, 20, 23-30.	3.1	50

#	ARTICLE	IF	PR CITATIONS
127	Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants. <i>Journal of Clinical Virology</i> , 2001, 20, 59-70.	3.1	69
128	Corrigendum to "Evaluation of diagnostic methods for detection of cytomegalovirus in recipients of allogeneic stem cell transplants" [JCV 20 (2001) 59-70]. <i>Journal of Clinical Virology</i> , 2001, 23, 117.	3.1	0
129	Enterovirus Infections in Germany: Comparative Evaluation of Different Laboratory Diagnostic Methods. <i>Infection</i> , 2001, 29, 138-142.	3.2	15
130	False-negative HIV antibody test results. , 2000, 60, 43-47.		16
131	Cytomegalovirus Infection Decreases Expression of Thrombospondin $\alpha$ 1 and $\alpha$ 2 in Cultured Human Retinal Glial Cells: Effects of Antiviral Agents. <i>Journal of Infectious Diseases</i> , 2000, 182, 643-651.	3.9	27
132	No apparent effect of cidofovir in epidermodysplasia verruciformis. <i>Journal of Clinical Virology</i> , 2000, 16, 55-57.	3.1	19
133	Übertragbare spongiforme Enzephalopathien: die Creutzfeldt-Jakob-Krankheit. <i>Chirurg</i> , 1998, 69, 511-521.	0.6	0
134	Fatal microcystin intoxication in haemodialysis unit in Caruaru, Brazil. <i>Lancet</i> , The, 1998, 352, 21-26.	52.0	698
135	Diphtheria immunity in health staff. <i>Lancet</i> , The, 1996, 347, 969.	52.0	9
136	Evaluation of 11 enzyme immunoassays for the detection of immunoglobulin M antibodies to Epstein-Barr virus. <i>Journal of Virological Methods</i> , 1996, 57, 87-93.	1.7	33
137	Lack of correlation between different hepatitis C virus screening and confirmatory assays. <i>Journal of Virological Methods</i> , 1996, 59, 141-146.	1.7	9
138	Unusual course of herpes simplex virus encephalitis after acyclovir therapy. <i>Infection</i> , 1996, 24, 384-389.	3.2	17
139	Prolonged Th2 cell activation and increased viral replication in HIV-Leishmania co-infected patients despite treatment. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1996, 90, 434-435.	1.4	47
140	Evaluation of the reliability of 6 current anti-HIV-1/HIV-2 enzyme immunoassays. <i>Journal of Virological Methods</i> , 1995, 55, 97-104.	1.7	21